Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Kallianos

Internal Medicine Durham, NC Medical Doctor

NPI 1245231588 CMS profile 328252

4309 Medical Park Dr, Suite 200, Durham, NC 27704

Open in the dashboard

General payments

$8,381

498 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Kallianos of Durham, NC is reported in the CMS Open Payments database as having received $8,381 across 498 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,104 60
2024 General $1,308 72
2023 General $1,238 69
2022 General $1,390 79
2021 General $1,236 78
2020 General $1,154 75
2019 General $951 65

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Kallianos
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to John Kallianos were reported at $1,104. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year John Kallianos Internal Medicine median Middle half National median
2019 $951 $159 $48–$570 $163
2020 $1,154 $119 $33–$402 $114
2021 $1,236 $135 $37–$521 $132
2022 $1,390 $141 $42–$496 $149
2023 $1,238 $149 $45–$519 $160
2024 $1,308 $154 $47–$537 $164
2025 $1,104 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,109 76 payments
  2. Pfizer Inc. $929 61 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $708 37 payments
  4. Lilly USA, LLC $706 42 payments
  5. AbbVie, Inc. $676 36 payments
  6. AstraZeneca Pharmaceuticals LP $399 27 payments
  7. Sanofi-Aventis U.S. LLC $333 19 payments
  8. Amgen Inc. $267 16 payments
  9. Janssen Pharmaceuticals, Inc $242 14 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $242 13 payments
  11. Other $2,771 157 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,346 497 payments
  2. Education $35 1 payment
Products named General payments · program years 2019–2025
  1. Ozempic $660 44 payments
  2. RYBELSUS $507 35 payments
  3. NURTEC ODT $495 31 payments
  4. MOUNJARO $380 21 payments
  5. JARDIANCE Diabetes $379 20 payments
  6. ELIQUIS $347 24 payments
  7. UBRELVY $292 15 payments
  8. JARDIANCE Diabetes $291 18 payments
  9. ZEPBOUND $282 17 payments
  10. FARXIGA $248 17 payments
  11. Other $8,041 481 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 196 drugs

Part D claims

15,942

Median for Internal Medicine: 777

Drug cost

$1,124,774

Median for Internal Medicine: $73,373

Branded share of claims

23.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 276 $201,904
Jardiance Empagliflozin Brand 128 $144,248
Ozempic Semaglutide Brand 110 $111,976
Xarelto Rivaroxaban Brand 73 $73,194
Januvia Sitagliptin Phosphate Brand 43 $58,258
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 77 $52,065
Tresiba Flextouch U-200 Insulin Degludec Brand 33 $31,730
Rybelsus Semaglutide Brand 20 $30,496
Rexulti Brexpiprazole Brand 20 $27,983
Linzess Linaclotide Brand 35 $27,010

The 10 drugs with the highest cost, of 196 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$124,758

Of which drugs: $380

Medicare patients

432

Average age 75

Services billed

12,536

218 women, 214 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 41%
Diabetes 36%
Chronic kidney disease 34%
Depression 29%
Ischemic heart disease 24%
Atrial fibrillation 17%
Cancer 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 32 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $110
$110 — —
VRAYLAR
  • AbbVie, Inc. $101
$101 — —
JARDIANCE
  • Lilly USA, LLC $62
  • Boehringer Ingelheim Pharmaceuticals, Inc. $32
$94 128 —
NURTEC ODT
  • PFIZER INC. $76
$76 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $49
  • Lundbeck LLC $21
$70 20 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 32 with Patron

Records

498 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record